In tumours treated with enzalutamide alone or with a combination of enzalutamide and CT7001, GSEA identified negative enrichment of several gene sets, including the hallmark androgen response, MYC targets, reactive oxygen species and fatty acid metabolism (Fig. 6d). The gene discussed is MYC; the disease is neoplasm.